Bone Biologics Corp (BBLG, BBLGW (BBLG) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$0.38

From 52W high−83.56%

Volume14759.00

Market cap$1.18M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$0.38

From 52W high

−83.56%

Volume

14759.00

Market cap

$1.18M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.7x

P/E (TTM)

—

RSI (14)

27.1

MomentumView details →

1D Return

−1.87%

YTD Return

−75.86%

SummaryUpdated Sep 1, 2026

Bone Biologics Corporation (NASDAQ:BBLG) is a clinical-stage medical device company founded in 2004 and headquartered in Burlington, Massachusetts. The company went public in October 2021 and focuses on developing innovative bone regeneration solutions for spinal fusion procedures. Bone Biologics operates as a pre-revenue biotechnology company, dedicating its efforts to advancing a proprietary recombinant protein technology that aims to enhance bone healing outcomes in orthopedic surgery.

Ask drillr about Bone Biologics Corp (BBLG, BBLGW →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

1.7x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−47.75%

ROA (TTM)

−44.18%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+33.60%

FCF YoY

+22.83%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+45.13%

EBITDA YoY

+10.76%

MomentumView details →

1D Return

−1.87%

YTD Return

−75.86%

1Y Return

−82.59%

RSI (14)

27.1

vs 50D SMA

−26.87%

vs 200D SMA

−66.38%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

13.38x

Quick Ratio

13.38x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.17

EPS Surprise

10.53%

Beats (12Q)

7/12

Next Q EPS Est

−$0.15

Avg Surprise (4Q)

5.16%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−2.84M

Op. CF (TTM)

−2.57M

Next earningsMar 1, 2027 →

Latest newsMore news →

Bone Biologics Corporation announced that six hospital sites in Australia have agreed to participate in its first-in-human pilot clinical trial of NB1, its rhNELL-1-based bone graft product for spinal fusion.57d ago

Similar companies

NanoVibronix, Inc.NAOV Nexalin Technology, Inc.NXL Allurion Technologies Inc.ALUR Holdco Nuvo Group D.G Ltd. Ordinary SharesNUVO Nuwellis, Inc.NUWE INVO Fertility, Inc.IVF Find similar companies →

Latest newsMore news →

Bone Biologics Corp received a NASDAQ notice dated September 10, 2026 that it no longer complies with the minimum bid price requirement under Listing Rule 5550(a)(2), and intends to seek stockholder approval for a reverse stock split at its upcoming annual meeting.49d ago Bone Biologics Corporation announced that six hospital sites in Australia have agreed to participate in its first-in-human pilot clinical trial of NB1, its rhNELL-1-based bone graft product for spinal fusion.57d ago